Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma Forty-seven ...
SAN FRANCISCO, CA and ANN ARBOR, MI--Medivation, Inc. (NASDAQ: MDVN) and OncoFusion Therapeutics, Inc. today announced that they have entered into a research and license agreement for certain ...
Bromodomains are epigenetic reader proteins that recognize acetylated histone tails, playing a key role in chromatin remodeling and gene regulation. Through these mechanisms, they influence the ...
Circulation cell-free tumor DNA and extra-tumor heterogeneity in post-mortem examination. Low-coverage, genome-wide sequencing of cell-free DNA developed for noninvasive prenatal testing (NIPT) to ...
ANN ARBOR, Mich. — Prostate cancer becomes deadly when anti-hormone treatments stop working. Now a new study suggests a way to block the hormones at their entrance. Researchers from the University of ...
OPN-6602 is Currently in a Phase 1 Clinical Trial for Relapsed/Refractory Multiple Myeloma SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–February 12, 2025– Opna Bio, a clinical-stage biopharmaceutical ...
Appoints Axel Bolte, MBA, MSc, to Board Director and Stephanie Oestreich, PhD, MPA, to Board Observer SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–August 26, 2024– Opna Bio announced that it has dosed ...
Type 1 diabetes is an autoimmune disease leading to the destruction of insulin-producing pancreatic beta cells and subsequent hyperglycemia. Lifelong insulin treatment and long-term complications take ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results